According to a recent article in The Manila Times, Jade Biosciences has begun dosing participants in a Phase 2 clinical study, known as JUNIPER, evaluating
An article from Medscape highlighted recent advances in treatment that are reshaping the clinical approach to epidermolysis bullosa (EB), transitioning care from largely supportive management
A recent article by BioPharmaDive highlighted a mid-stage clinical trial that evaluted an investigational Parkinson’s disease therapy co-developed by Biogen and Denali Therapeutics, and that
Johnson & Johnson announced FDA approval of a supplemental new drug application for Caplyta (lumateperone) for the prevention of relapse in schizophrenia, based on compelling
A growing body of research highlights the broader benefits of human papillomavirus (HPV) vaccination beyond its long-standing focus on cervical cancer prevention. A recent large-scale
According to a recent article by The Manila Times, Design Therapeutics has reported encouraging interim results from its ongoing Phase 1/2 RESTORE-FA study, highlighting both
Novartis and PTC Therapeutics have advanced their Huntington’s disease candidate, votoplam, into Phase 3 development following promising mid-stage results. The decision reflects confidence in the
As reported on MedicalXpress, a newly developed RNA-focused analytical method may improve the detection and characterization of repeat expansion disorders, a group of genetic conditions
A recent article from The Manila Times highlighted findings from the ongoing IMPACT‑TD Registry underscore a persistent gap in diagnosing tardive dyskinesia (TD), particularly among
BridgeBio’s Attruby (acoramidis) is positioning itself as a formidable competitor in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, with new pivotal trial data and indirect comparisons
A recent article from SciTechDaily describes the promising approach instituted at a private, non-profit biomedical research firm in San Francisco that incorporates data science, AI,
According to a recent press release, Artios Pharma has begun dosing patients in a global Phase 2 clinical trial evaluating its investigational DNA polymerase theta
A significant advancement in antiviral therapy has emerged with the successful development of a CRISPR-Cas13d-based system designed to combat hepatitis E virus (HEV) infections. This
In a recent press release from Pfizer, it was shared that the European Commission (EC) has broadened the approved use of Pfizer’s marstacimab (brand name
A recent report by the Manila Times highlighted Madrigal Pharmaceuticals’ unveiling of a series of new analyses and real-world findings supporting the therapeutic profile of
UniQure has announced plans to submit its groundbreaking Huntington’s disease gene therapy, AMT-130, for regulatory approval in the United Kingdom later this year, marking a
According to a recent report on MedTechDive, Guardant Health has received U.S. Food and Drug Administration (FDA) approval for an updated version of its liquid
📱 This or That? ✍️
When you're getting ready for an appointment, how do you keep track of your questions?
📱 Notes App – Easy to update on the go and always within reach.
✍️ Handwritten List – Simple, personal, and satisfying to check off.
No matter which you choose, writing down your questions ahead of time can help you feel more prepared and make the most of your appointment.
👇 Tell us in the comments: Team Notes App or Team Handwritten List?
#thisorthat #PatientTips #appointmentprep #PatientWorthy #raredisease #chronicillness
Today, on International Dravet Syndrome Awareness Day, we recognize the strength of individuals and families navigating this rare and severe form of epilepsy. By raising awareness, sharing knowledge, and supporting research, we can help create a better future for those affected by Dravet syndrome!
#DravetSyndromeAwarenessDay #DravetSyndrome #rarediseaseawareness #rarediseaseoftheweek #raredisease #PatientWorthy
People often see the appointments.
What they don't always see is everything that comes with them.
The scheduling. The rescheduling. The insurance calls. The paperwork. The reminders. The pharmacy pickups. The waiting on hold.
Sometimes managing the logistics can take as much energy as managing the condition itself.
If this part feels exhausting, you're not imagining it—and you're definitely not alone.
#chronicillness #invisibleillness #raredisease #youarenotalone #PatientWorthy
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
